Scilex Holding Company (SCLX) has shared an announcement.
Scilex Holding Company’s Board has greenlit management to investigate strategic options for enhancing the value of its subsidiary, Semnur Pharmaceuticals, and its main product, SEMDEXA™. Potential strategies include a spin-off, merger, or similar transactions, with consideration for distributing up to 10% of Scilex’s stake in Semnur to stockholders. While the process for a possible dividend is in motion, details will be disclosed in accordance with legal and Nasdaq requirements as events unfold.
Find detailed analytics on SCLX stock on TipRanks’ Stock Analysis page.
